NOVN.CH

98.28

+1.57%↑

LONN.CH

584.2

+0.27%↑

SOON.CH

291.7

+0.48%↑

NOVN.CH

98.28

+1.57%↑

LONN.CH

584.2

+0.27%↑

SOON.CH

291.7

+0.48%↑

NOVN.CH

98.28

+1.57%↑

LONN.CH

584.2

+0.27%↑

SOON.CH

291.7

+0.48%↑

NOVN.CH

98.28

+1.57%↑

LONN.CH

584.2

+0.27%↑

SOON.CH

291.7

+0.48%↑

NOVN.CH

98.28

+1.57%↑

LONN.CH

584.2

+0.27%↑

SOON.CH

291.7

+0.48%↑

Search

Sandoz Group AG

Closed

41.72 -0.83

Overview

Share price change

24h

Current

Min

41.66

Max

41.81

Key metrics

By Trading Economics

Income

75M

150M

Sales

2.5B

5.1B

Dividend yield

1.06

Profit margin

2.963

Employees

22,633

EBITDA

271M

541M

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.06%

3.09%

Next Earnings

12 Mar 2025

Market Stats

By TradingEconomics

Market Cap

19B

Previous open

42.55

Previous close

41.72

Sandoz Group AG Chart

Past performance is not a reliable indicator of future results.

Related News

17 Dec 2024, 07:45 UTC

Market Talk

Sandoz's U.S. Settlement to Cost 1.1 Swiss Francs a Share -- Market Talk

17 Dec 2024, 07:34 UTC

Market Talk

Sandoz's U.S. Settlement Shows Commitment Move Forward -- Market Talk

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Comparison

Price change

Sandoz Group AG Forecast

Financials

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.